330 related articles for article (PubMed ID: 30765888)
1. Epigenetic drugs and their molecular targets in testicular germ cell tumours.
Jostes S; Nettersheim D; Schorle H
Nat Rev Urol; 2019 Apr; 16(4):245-259. PubMed ID: 30765888
[TBL] [Abstract][Full Text] [Related]
2. The bromodomain inhibitor JQ1 triggers growth arrest and apoptosis in testicular germ cell tumours in vitro and in vivo.
Jostes S; Nettersheim D; Fellermeyer M; Schneider S; Hafezi F; Honecker F; Schumacher V; Geyer M; Kristiansen G; Schorle H
J Cell Mol Med; 2017 Jul; 21(7):1300-1314. PubMed ID: 28026145
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic treatment combinations to effectively target cisplatin-resistant germ cell tumors: past, present, and future considerations.
Oing C; Skowron MA; Bokemeyer C; Nettersheim D
Andrology; 2019 Jul; 7(4):487-497. PubMed ID: 30924611
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic alterations of testicular germ cell tumours.
Ilijazi D; Shariat SF; Hassler MR; Lemberger U; Ertl IE
Curr Opin Urol; 2020 Mar; 30(2):264-270. PubMed ID: 31905176
[TBL] [Abstract][Full Text] [Related]
5. Therapeutical interference with the epigenetic landscape of germ cell tumors: a comparative drug study and new mechanistical insights.
Müller MR; Burmeister A; Skowron MA; Stephan A; Bremmer F; Wakileh GA; Petzsch P; Köhrer K; Albers P; Nettersheim D
Clin Epigenetics; 2022 Jan; 14(1):5. PubMed ID: 34996497
[TBL] [Abstract][Full Text] [Related]
6. Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine.
Albany C; Hever-Jardine MP; von Herrmann KM; Yim CY; Tam J; Warzecha JM; Shin L; Bock SE; Curran BS; Chaudhry AS; Kim F; Sandusky GE; Taverna P; Freemantle SJ; Christensen BC; Einhorn LH; Spinella MJ
Oncotarget; 2017 Jan; 8(2):2949-2959. PubMed ID: 27936464
[TBL] [Abstract][Full Text] [Related]
7. Animacroxam, a Novel Dual-Mode Compound Targeting Histone Deacetylases and Cytoskeletal Integrity of Testicular Germ Cell Cancer Cells.
Steinemann G; Dittmer A; Kuzyniak W; Hoffmann B; Schrader M; Schobert R; Biersack B; Nitzsche B; Höpfner M
Mol Cancer Ther; 2017 Nov; 16(11):2364-2374. PubMed ID: 28838999
[TBL] [Abstract][Full Text] [Related]
8. Deciphering the molecular effects of romidepsin on germ cell tumours: DHRS2 is involved in cell cycle arrest but not apoptosis or induction of romidepsin effectors.
Nettersheim D; Berger D; Jostes S; Skowron M; Schorle H
J Cell Mol Med; 2019 Jan; 23(1):670-679. PubMed ID: 30460772
[TBL] [Abstract][Full Text] [Related]
9. Targeting histone deacetylases in testicular germ cell tumours: an encouraging treatment approach for the future
Tavares NT; Henrique R; Jerónimo C; Lobo J
J Pathol; 2023 Feb; 259(2):115-118. PubMed ID: 36426822
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer.
Nitzsche B; Gloesenkamp C; Schrader M; Hoffmann B; Zengerling F; Balabanov S; Honecker F; Höpfner M
Br J Cancer; 2012 Nov; 107(11):1853-63. PubMed ID: 23169338
[TBL] [Abstract][Full Text] [Related]
11. Genome-scale CRISPR screen reveals neddylation to contribute to cisplatin resistance of testicular germ cell tumours.
Funke K; Einsfelder U; Hansen A; Arévalo L; Schneider S; Nettersheim D; Stein V; Schorle H
Br J Cancer; 2023 Jun; 128(12):2270-2282. PubMed ID: 37024667
[TBL] [Abstract][Full Text] [Related]
12. Involvement of the DNA mismatch repair system in cisplatin sensitivity of testicular germ cell tumours.
Rudolph C; Melau C; Nielsen JE; Vile Jensen K; Liu D; Pena-Diaz J; Rajpert-De Meyts E; Rasmussen LJ; Jørgensen A
Cell Oncol (Dordr); 2017 Aug; 40(4):341-355. PubMed ID: 28536927
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic alterations as therapeutic targets in Testicular Germ Cell Tumours : current and future application of 'epidrugs'.
Cardoso AR; Lobo J; Miranda-Gonçalves V; Henrique R; Jerónimo C
Epigenetics; 2021 Apr; 16(4):353-372. PubMed ID: 32749176
[TBL] [Abstract][Full Text] [Related]
14. Novel epigenetically deregulated genes in testicular cancer include homeobox genes and SCGB3A1 (HIN-1).
Lind GE; Skotheim RI; Fraga MF; Abeler VM; Esteller M; Lothe RA
J Pathol; 2006 Dec; 210(4):441-9. PubMed ID: 17029216
[TBL] [Abstract][Full Text] [Related]
15. Testicular germ-cell cancer.
Horwich A; Shipley J; Huddart R
Lancet; 2006 Mar; 367(9512):754-65. PubMed ID: 16517276
[TBL] [Abstract][Full Text] [Related]
16. Influence of vitamin D on cisplatin sensitivity in testicular germ cell cancer-derived cell lines and in a NTera2 xenograft model.
Jørgensen A; Blomberg Jensen M; Nielsen JE; Juul A; Rajpert-De Meyts E
J Steroid Biochem Mol Biol; 2013 Jul; 136():238-46. PubMed ID: 23098692
[TBL] [Abstract][Full Text] [Related]
17. Molecular Mechanisms of Cisplatin Chemoresistance and Its Circumventing in Testicular Germ Cell Tumors.
Schmidtova S; Kalavska K; Kucerova L
Curr Oncol Rep; 2018 Sep; 20(11):88. PubMed ID: 30259297
[TBL] [Abstract][Full Text] [Related]
18. IGF1R signalling in testicular germ cell tumour cells impacts on cell survival and acquired cisplatin resistance.
Selfe J; Goddard NC; McIntyre A; Taylor KR; Renshaw J; Popov SD; Thway K; Summersgill B; Huddart RA; Gilbert DC; Shipley JM
J Pathol; 2018 Feb; 244(2):242-253. PubMed ID: 29160922
[TBL] [Abstract][Full Text] [Related]
19. Molecular Mechanisms of Resistance in Testicular Germ Cell Tumors - clinical Implications.
Kalavska K; Conteduca V; De Giorgi U; Mego M
Curr Cancer Drug Targets; 2018; 18(10):967-978. PubMed ID: 29295694
[TBL] [Abstract][Full Text] [Related]
20. Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance.
Mueller T; Mueller LP; Luetzkendorf J; Voigt W; Simon H; Schmoll HJ
Tumour Biol; 2006; 27(2):71-83. PubMed ID: 16557044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
